Trial · NCT07913269
Heart and Brain Blood Flow in Obstructive Sleep Apnea
NCT07913269, Not yet recruiting, Copenhagen University Hospital, Rigshospitalet
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Heart and Brain Blood Flow in Obstructive Sleep Apnea. Trials, record NCT07913269. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Heart and Brain Blood Flow in Obstructive Sleep Apnea
- NCT number
- NCT07913269
- Status
- Not yet recruiting
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Conditions
- Obstructive Sleep Apnea (OSA)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in volumetric blood flow rate during spontaneous obstructive apneas | At baseline and after 6 months CPAP treatment | Percentage change in volumetric blood flow rate Q(t), measured with real time 2D phase contrast MRI in the ascending aorta, superior vena cava, bilateral internal carotid arteries, bilateral vertebral arteries, bilateral internal jugular veins and superior sagittal sinus. Each vessel is assessed separately by comparing the baseline immediately before an event with phases of obstructive effort, desaturation and apnea termination. The analysis is restricted to participants with OSA. At least three usable obstructive apneas per location or measurement plane are targeted. |
| Primary | Change in peak blood velocity during spontaneous obstructive apneas | At baseline and after 6 months CPAP treatment | Percentage change in peak blood velocity, measured with real time 2D phase contrast MRI in the ascending aorta, superior vena cava, bilateral internal carotid arteries, bilateral vertebral arteries, bilateral internal jugular veins and superior sagittal sinus. Each vessel is assessed separately by comparing the baseline immediately before an event with phases of obstructive effort, desaturation and apnea termination. Underlying velocity measurements are expressed in cm/s. The analysis is restricted to participants with OSA. |
| Secondary | Blood flow rate response to Mueller and Valsalva maneuvers | At baseline | Change in volumetric blood flow rate from the local baseline during Mueller and Valsalva maneuvers, reported separately for each maneuver and vessel. Real time 2D phase contrast MRI measures the ascending aorta, superior vena cava, bilateral internal carotid, vertebral and internal jugular vessels, and superior sagittal sinus. Responses are compared between OSA and control participants. |
| Secondary | Peak blood velocity response to Mueller and Valsalva maneuvers | At baseline | Change in peak blood velocity from the local baseline during Mueller and Valsalva maneuvers, reported separately for each maneuver and vessel. Underlying velocity measurements are expressed in cm/s. Responses in the target chest, neck and intracranial vessels are compared between OSA and control participants. |
| Secondary | Total cerebral blood flow (TCBF) | At baseline and after 6 months CPAP treatment | Total cerebral blood flow in mL/min, calculated as the sum of bilateral internal carotid and vertebral artery flow using 4D flow MRI. Resting values without CPAP are compared between OSA and control participants. Within the OSA group, changes from without CPAP to during CPAP are assessed, with control values providing a reference. |
| Secondary | Arterial and venous blood flow | At baseline and after 6 months CPAP treatment | Mean arterial and venous volumetric flow rate in mL/min, measured using 4D flow MRI at the intracranial, neck and thoracic levels. Each vessel is assessed separately. Resting values without CPAP are compared between OSA and control participants. Within the OSA group, changes from without CPAP to during CPAP are assessed. |
| Secondary | Perivascular space burden | At baseline and after 6 months CPAP treatment | Perivascular space burden assessed on structural MRI and compared between OSA and control participants. Total burden and regional burden in the basal ganglia and centrum semiovale are reported separately, using prespecified definitions and the same rating or quantification method in both groups. |
| Secondary | DTI-ALPS index | At baseline and after 6 months CPAP treatment | Dimensionless diffusion tensor imaging analysis along the perivascular space index, calculated separately in each hemisphere. The mean of the left and right indices is compared between OSA and controls; side specific values are supplementary. |
| Other | Cerebral lactate during rest and the sleep recording block | At baseline and after 6 months CPAP treatment | Cerebral lactate measured with proton magnetic resonance spectroscopy during a resting acquisition and sleep. A corresponding water reference is acquired. Apneas and participant state during the block are annotated. The sleep spectrum is a block measurement unless separate event specific spectra are technically available and validated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913269
GET https://conductscience.org/api/trials/v1/NCT07913269/registered